Juan J. Valdés-Andrade, Facultad de Medicina, Laboratorio de Investigación en Nutrición, Universidad Autónoma del Estado de México (UAEMéx), Toluca, Edo. de México, México
Beatriz E. Martínez-Carrillo, Facultad de Medicina, Laboratorio de Investigación en Nutrición, Universidad Autónoma del Estado de México (UAEMéx), Toluca, Edo. de México, México
Rosa A. Jarillo-Luna, Escuela Superior de Medicina, Laboratorio de Morfología, Sección de Estudios de Posgrado e Investigación, Instituto Politécnico Nacional, Ciudad de México, México
Arturo García-Rillo, Escuela Superior de Medicina, Laboratorio de Morfología, Sección de Estudios de Posgrado e Investigación, Instituto Politécnico Nacional, Ciudad de México, México
Juan M. Medina-Castro, Departamento de Cirugía Oncológica, Grupo Oncológico de Toluca, Hospital Centro Médico Toluca, Metepec, Edo. de México, México
José A. Castillo-Cardiel, Jefatura de Enseñanza, Hospital MAC Irapuato, Gto., México
Cristian A. Rosales-Gómez, Escuela Superior de Medicina, Laboratorio de Morfología, Sección de Estudios de Posgrado e Investigación, Instituto Politécnico Nacional, Ciudad de México, México
Background: Baseline determination of inflammatory status at diagnosis in patients with early breast cancer (EBC) may be useful as a prognostic factor. Objectives: To identify the inflammatory status of Mexican women with EBC using the neutrophil- lymphocyte index (NLI), platelet-lymphocyte ratio (PLR), and body mass index as predictors of disease recurrence. Methods: A cross-sectional, observational, and retrospective study was conducted. Clinicopathological and baseline biochemical data were collected from 857 patients with EBC from January 2013 to December 2020 at the State Cancer Center. Patients were stratified into two groups according to the optimal cutoff value for NLI and PLR, determined using ROC curve analysis. Results: Patients with a high NLI showed a shorter disease-free period (DFP) (p = 0.010). Overweight/obesity, clinical stage, and triple-negative molecular subtype were associated with a worse DFP (p = 0.043, p = 0.046, and p = 0.001, respectively). Clinical stage, triple-negative molecular subtype, and a high NLI value were independent prognostic factors related to DR. Conclusions: Baseline NLI determination proved useful as a complementary prognostic tool in Mexican patients with EBC.
Keywords: Early breast cancer. Neutrophil lymphocyte index. Platelet lymphocyte rate. Body mass index. Disease recurrence.
